These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11705875)

  • 1. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
    Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
    Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.
    Rolland D; Camara-Clayette V; Barbarat A; Salles G; Coiffier B; Ribrag V; Thieblemont C
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):855-63. PubMed ID: 17639395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
    Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M
    Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
    Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A
    Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
    Delmas C; End D; Rochaix P; Favre G; Toulas C; Cohen-Jonathan E
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6062-8. PubMed ID: 14676133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Br J Pharmacol; 2004 Sep; 143(2):318-30. PubMed ID: 15339863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
    Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
    J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
    Smith V; Rowlands MG; Barrie E; Workman P; Kelland LR
    Clin Cancer Res; 2002 Jun; 8(6):2002-9. PubMed ID: 12060646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
    Ochiai N; Uchida R; Fuchida S; Okano A; Okamoto M; Ashihara E; Inaba T; Fujita N; Matsubara H; Shimazaki C
    Blood; 2003 Nov; 102(9):3349-53. PubMed ID: 12842991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.
    Izbicka E; Campos D; Carrizales G; Patnaik A
    Anticancer Res; 2005; 25(5):3215-23. PubMed ID: 16101130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
    Venkatasubbarao K; Choudary A; Freeman JW
    Cancer Res; 2005 Apr; 65(7):2861-71. PubMed ID: 15805288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.
    Venet M; End D; Angibaud P
    Curr Top Med Chem; 2003; 3(10):1095-102. PubMed ID: 12769710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.